Dimensional Fund Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$84.9M Sell
425,230
-7,762
-2% -$1.54M 0.02% 1173
2025
Q4
$81.9M Sell
432,992
-90,921
-17% -$17.5M 0.02% 1210
2025
Q3
$92.8M Sell
523,913
-180,609
-26% -$26.8M 0.02% 1132
2025
Q2
$80.1M Sell
704,522
-40,408
-5% -$4.32M 0.02% 1185
2025
Q1
$78.3M Buy
744,930
+21,911
+3% +$2.48M 0.02% 1163
2024
Q4
$77.5M Buy
723,019
+16,003
+2% +$1.81M 0.02% 1240
2024
Q3
$70.8M Sell
707,016
-1,608
-0.2% -$162K 0.02% 1283
2024
Q2
$59.7M Buy
708,624
+44,543
+7% +$3.54M 0.02% 1346
2024
Q1
$48.5M Buy
664,081
+2,783
+0.4% +$205K 0.01% 1471
2023
Q4
$47.2M Buy
661,298
+46,906
+8% +$2.77M 0.01% 1489
2023
Q3
$36.8M Buy
614,392
+82,970
+16% +$5.46M 0.01% 1541
2023
Q2
$38.3M Buy
531,422
+61,506
+13% +$4.61M 0.01% 1540
2023
Q1
$34.6M Buy
469,916
+11,993
+3% +$853K 0.01% 1600
2022
Q4
$30.6K Sell
457,923
-262,013
-36% -$17M 0.01% 1641
2022
Q3
$38.7M Buy
719,936
+10,281
+1% +$604K 0.01% 1425
2022
Q2
$39.5M Buy
709,655
+103,532
+17% +$5.88M 0.01% 1473
2022
Q1
$42.5M Buy
606,123
+8,736
+1% +$634K 0.01% 1537
2021
Q4
$57.6M Sell
597,387
-170
-0% -$15.7K 0.02% 1314
2021
Q3
$51.9M Sell
597,557
-58,674
-9% -$4.54M 0.02% 1388
2021
Q2
$53.7M Buy
656,231
+75,533
+13% +$6.28M 0.02% 1392
2021
Q1
$55.2M Sell
580,698
-5,665
-1% -$536K 0.02% 1365
2020
Q4
$36.4M Sell
586,363
-22,519
-4% -$1.28M 0.01% 1617
2020
Q3
$36.2M Sell
608,882
-4,086
-0.7% -$279K 0.02% 1457
2020
Q2
$42.8M Sell
612,968
-127,798
-17% -$8.1M 0.02% 1334
2020
Q1
$33.6M Sell
740,766
-11,629
-2% -$659K 0.02% 1378
2019
Q4
$49M Buy
752,395
+122,187
+19% +$8.17M 0.02% 1463
2019
Q3
$39.1M Buy
630,208
+256,368
+69% +$16.1M 0.02% 1596
2019
Q2
$26.6M Buy
373,840
+33,839
+10% +$2.49M 0.01% 1889
2019
Q1
$26.7M Buy
340,001
+7,689
+2% +$583K 0.01% 1894
2018
Q4
$28.1M Buy
332,312
+51,450
+18% +$5.48M 0.01% 1780
2018
Q3
$48.1M Sell
280,862
-38,271
-12% -$5.77M 0.02% 1500
2018
Q2
$41.2M Sell
319,133
-37,191
-10% -$4.15M 0.02% 1620
2018
Q1
$36.7M Sell
356,324
-5,901
-2% -$584K 0.02% 1662
2017
Q4
$30.9M Sell
362,225
-17,894
-5% -$1.55M 0.01% 1799
2017
Q3
$32.3M Sell
380,119
-42,425
-10% -$3.36M 0.01% 1729
2017
Q2
$32M Sell
422,544
-7,291
-2% -$510K 0.01% 1690
2017
Q1
$28.4M Sell
429,835
-303
-0.1% -$19.9K 0.01% 1740
2016
Q4
$27.3M Sell
430,138
-877
-0.2% -$55.3K 0.01% 1738
2016
Q3
$27.4M Sell
431,015
-29,995
-7% -$2.2M 0.01% 1656
2016
Q2
$34.3M Sell
461,010
-126,438
-22% -$9.38M 0.02% 1367
2016
Q1
$39.2M Sell
587,448
-296,074
-34% -$18M 0.02% 1196
2015
Q4
$59.8M Sell
883,522
-13,770
-2% -$850K 0.04% 692
2015
Q3
$47.9M Buy
897,292
+13,627
+2% +$827K 0.03% 841
2015
Q2
$55.6M Buy
883,665
+51,476
+6% +$2.81M 0.03% 761
2015
Q1
$40M Buy
832,189
+135,116
+19% +$5.18M 0.03% 1066
2014
Q4
$23.1M Buy
697,073
+60,514
+10% +$1.97M 0.02% 1603
2014
Q3
$18.7M Buy
636,559
+41,144
+7% +$1.37M 0.01% 1706
2014
Q2
$23.1M Buy
595,415
+241,203
+68% +$9.79M 0.02% 1508
2014
Q1
$14.9M Buy
354,212
+151,133
+74% +$6.3M 0.01% 1858
2013
Q4
$6.66M Buy
203,079
+201,715
+14,788% +$6.57M 0.01% 2428
2013
Q3
$37K Hold
1,364
﹤0.01% 3462
2013
Q2
$32K Buy
+1,364
New +$24.5K ﹤0.01% 3464

Other funds holding LGND

Dimensional Fund Advisors's LGND Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 1.8% in Q1 2026, selling an estimated $1.54M and leaving 425,230 shares worth $84.9M. The position accounts for 0.02% of the portfolio, ranked #1173.

Dimensional Fund Advisors first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $92.8M in Q3 2025. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Dimensional Fund Advisors held 425,230 shares of Ligand Pharmaceuticals worth $84.9M as of Q1 2026.
  • Dimensional Fund Advisors sold 7,762 Ligand Pharmaceuticals shares in Q1 2026, an estimated $1.54M.
  • Ligand Pharmaceuticals made up 0.02% of Dimensional Fund Advisors's portfolio in Q1 2026, its #1173 holding.
  • Dimensional Fund Advisors first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Dimensional Fund Advisors's Ligand Pharmaceuticals position peaked at $92.8M in Q3 2025.
  • 358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.